Literature DB >> 6805933

Cimetidine and plasma levels of gonadotropins, prolactin and gonadal steroids in women.

S Bélisle, M Patry, L Tétreault.   

Abstract

The endocrine effects of cimetidine (Tagamet) during the menstrual cycle were investigated in seven healthy female volunteers. The subjects were studied for six menstrual cycles divided into the pretreatment phase, a phase of therapy with 1.2 g of orally administered cimetidine daily for two cycles, and a post-treatment phase. Cimetidine therapy induced a significant increase in the mean plasma level of follicle-stimulating hormone during the periovulatory period, followed by modest but sustained hyperprolactinemia throughout the luteal phase of each cycle. No significant changes were found in the mean plasma levels of luteinizing hormone and progesterone, and the mean plasma estradiol level was significantly decreased only in the midproliferative phase of each cycle. The mean plasma prolactin levels after a bolus injection of thyrotropin-releasing hormone in the midluteal phase during cimetidine administration did not differ from the mean control levels, which indicates that cimetidine modulates the release of prolactin at the suprapituitary locus. However, the significance of the endocrine changes remains to be established.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805933      PMCID: PMC1863176     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  13 in total

1.  Letter: Breast changes in males on cimetidine.

Authors:  W H Hall
Journal:  N Engl J Med       Date:  1976-10-07       Impact factor: 91.245

Review 2.  Drug therapy: Cimetidine.

Authors:  W Finkelstein; K J Isselbacher
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

3.  Gynaecomastia with cimetidine.

Authors:  G F Delle Fave; G Tamburrano; L De Magistris; C Natoli; M L Santoro; R Carratu; A Torsoli
Journal:  Lancet       Date:  1977-06-18       Impact factor: 79.321

4.  Galactorrhoea with cimetidine.

Authors:  M C Bateson; M C Browning; A Maconnachie
Journal:  Lancet       Date:  1977-07-30       Impact factor: 79.321

5.  Safety of cimetidine.

Authors:  D M Kruss; A Littman
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

6.  Serum-prolactin in patients receiving chronic oral cimetidine.

Authors:  A M Spiegel; R Lopatin; S Peikin; D McCarthy
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

7.  Treatment of hirsute women with cimetidine.

Authors:  R A Vigersky; I Mehlman; A R Glass; C E Smith
Journal:  N Engl J Med       Date:  1980-10-30       Impact factor: 91.245

8.  Effects of cimetidine on prolactin, LH, and sex steroid secretion in male and female volunteers.

Authors:  H G Bohnet; M Greiwe; J P Hanker; C Aragona; H P Schneider
Journal:  Acta Endocrinol (Copenh)       Date:  1978-07

9.  Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine.

Authors:  D H Van Thiel; J S Gavaler; W I Smith; G Paul
Journal:  N Engl J Med       Date:  1979-05-03       Impact factor: 91.245

10.  Prolactin release by intravenous cimetidine in man: evidence for a suprapituitary locus on action.

Authors:  C Ferrari; R Caldara; C Barbieri; M Cambielli; L Bierti; M Romussi
Journal:  Clin Endocrinol (Oxf)       Date:  1979-12       Impact factor: 3.478

View more
  1 in total

Review 1.  Adverse reactions and interactions with H2-receptor antagonists.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.